Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT study
- PMID: 40773777
- DOI: 10.1016/j.jns.2025.123641
Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT study
Abstract
Background and purpose: Understanding the causes of recurrent ischemic events in patients with minor stroke or high-risk TIA is crucial to understand unmet needs in secondary prevention. This study examines the characteristics and causes of recurrences after non-cardioembolic minor stroke/high-risk TIA in patients treated with the best medical care.
Methods: This subgroup analysis from a prospective real-world study (READAPT, NCT05476081) included patients with non-cardioembolic minor ischemic stroke (NIHSS ≤5) or TIA (ABCD2 score ≥ 4), receiving short-term DAPT. We described the etiologic distribution according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification of the index and of the recurrent event. We analyzed baseline characteristics of patients with and without a 90-day ischemic recurrence to identify factors linked to recurrence.
Results: Out of 1641 patients, 56 (3.4 %) had a recurrent ischemic event (35 strokes and 21 TIAs). The cause of recurrences was undetermined in 21 (37.5 %), small vessel occlusion in 18 (32.1 %), large artery atherosclerosis in 11 (19.6 %), other determined in 3 (5.4 %), and cardioembolism in 3 (5.4 %). The etiologic distribution of recurrent events differed from that of the corresponding index events (p = 0.002). Non-compliance to DAPT was more prevalent in patients with recurrences compared with those without (8.9 % vs 3.7 %, p = 0.048).
Conclusions: Patients with recurrences after a minor stroke or high-risk TIA have a different etiologic distribution compared with their index events. Additionally, a lower compliance to DAPT was observed in those with recurrences, suggesting that adherence to DAPT should be encouraged to optimize the outcome of patients.
Keywords: Dual antiplatelet therapy; Ischemic stroke; Secondary prevention; Stroke etiopathogenesis; Transient ischemic attack.
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest Dr. Piscaglia reports grants from Sanofi Genzyme; grants from Roche Health Solutions Inc.; grants from Novartis Pharma; grants from Biogen; and grants from Merck Company Foundation. Dr. Paciaroni reports compensation from Boehringer Ingelheim for other services; compensation from PFIZER CANADA INC for other services; compensation from Bristol-Myers Squibb for other services; compensation from iRhythm Technologies for other services; compensation from SANOFIAVENTIS U.S. LLC for other services; and compensation from Daiichi Sankyo Europe GmbH for other services. Dr. Zini reports compensation from Bayer Healthcare for other services; compensation from Boehringer Ingelheim for consultant services; compensation from Alexion Pharmaceuticals for consultant services; and compensation from CSL Behring for consultant services. Dr. Ornello reports grants from Novartis; compensation from Teva Pharmaceutical Industries for other services; compensation from AbbVie for data and safety monitoring services; compensation from Teva Pharmaceutical Industries for other services; compensation from Eli Lilly and Company for other services; compensation from Novartis for other services; compensation from H. Lundbeck AS for other services; compensation from Eli LIlly for data and safety monitoring services; grants from Pfizer; grants from Allergan; travel support from Teva Pharmaceutical Industries; and compensation from Teva Pharmaceutical Industries for consultant services. Prof Sacco reports compensation from Novartis for other services; compensation from Novo Nordisk for consultant services; compensation from Boehringer Ingelheim for consultant services; compensation from Teva Pharmaceutical Industries for consultant services; compensation from Allergan for consultant services; employment by Università degli Studi dell'Aquila; compensation from Novartis for consultant services; compensation from Allergan for consultant services; compensation from PFIZER CANADA INC for consultant services; compensation from Abbott Canada for consultant services; compensation from H. Lundbeck A S for consultant services; compensation from AstraZeneca for consultant services; and compensation from Eli Lilly and Company for consultant services. The other authors report no conflicts.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical